Celcuity Inc

CELC

Company Profile

  • Business description

    Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

  • Contact

    16305 36th Avenue North
    Suite 100
    MinneapolisMN55446
    USA

    T: +1 763 392-0767

    E: [email protected]

    https://www.celcuity.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    87

Stocks News & Analysis

stocks

After earnings, is Alphabet stock a buy, a sell, or fairly valued?

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks

Moated ASX share crashes amid weak trading update

Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,015.4048.700.54%
CAC 407,875.4918.130.23%
DAX 4024,266.6349.260.20%
Dow JONES (US)44,558.6974.30-0.17%
FTSE 1009,129.466.86-0.08%
HKSE25,176.93347.52-1.36%
NASDAQ21,140.2841.990.20%
Nikkei 22540,654.7019.85-0.05%
NZX 50 Index12,855.9780.44-0.62%
S&P 5006,371.380.520.01%
S&P/ASX 2008,756.4051.800.60%
SSE Composite Index3,615.726.010.17%

Market Movers